Preliminary interpretive criteria for disk diffusion susceptibility testing of SCH 27899, a compound in the everninomicin class of antimicrobial agents

被引:4
作者
Cormican, MG
Marshall, SA
Jones, RN
机构
[1] Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA
关键词
D O I
10.1016/0732-8893(95)00171-9
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
As antimicrobial resistance among Grain-positive species becomes more common, alternative agents need to be developed for the therapy of serious infections. SCH 27899 is a compound from the everninomicin class of antimicrobial agents that possesses a potent Gram-positive spectrum. We evaluated three disk concentrations (0.25, 1, and 5 mu g) of three SCH 27899 formulations including SCH 27899 base (SCHB), N-methylglucamine SCH 27899 (NMG-SCH), and NMG-SCH complexed with hydroxypropyl beta-cyclodextrin. Disk zone diameters were correlated with minimum inhibitory concentration for 209 aerobic, nonfastidious Grain-positive stains and selected Gram-negative bacilli to develop disk diffusion interpretive criteria. No significant differences in activity were noted among the three SCH 27899 preparations. Of the three disk concentrations, the correlation coefficient was greatest (r = 0.88) for the 5-mu g SCHB disk test. For a tentative break point of less than or equal to 2 mu g SCHB/ml, preliminary disk interpretive criteria were: susceptible at greater than or equal to 12 mm, intermediate at 10-11 mm, and resistant at less than or equal to 9 mm (absolute categorical agreement, 99.5%). Zones were small secondary to drug solubility and diffusion limitations. Using these criteria for the SCHB 5-mu g disks, nearly all of the tested Gram-positive organisms were susceptible including methicillin-resistant staphylococci and vancomycin-resistant enterococci.
引用
收藏
页码:157 / 160
页数:4
相关论文
共 11 条
[1]  
BLACK J, 1964, ANTIMICROB AGENTS CH, P38
[2]   INCREASING PROBLEMS IN THE THERAPY OF ENTEROCOCCAL INFECTIONS [J].
ELIOPOULOS, GM .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1993, 12 (06) :409-412
[3]   CHEMICAL MODIFICATION OF EVERNINOMICINS [J].
GANGULY, AK ;
GIRIJAVALLABHAN, VM ;
MILLER, GH ;
SARRE, OZ .
JOURNAL OF ANTIBIOTICS, 1982, 35 (05) :561-570
[4]   EMERGING MULTIPLY RESISTANT ENTEROCOCCI AMONG CLINICAL ISOLATES .2. VALIDATION OF THE ETEST TO RECOGNIZE GLYCOPEPTIDE-RESISTANT STRAINS [J].
JONES, RN ;
ERWIN, ME ;
ANDERSON, SC .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 21 (02) :95-100
[5]   EMERGING MULTIPLY RESISTANT ENTEROCOCCI AMONG CLINICAL ISOLATES .1. PREVALENCE DATA FROM 97 MEDICAL-CENTER SURVEILLANCE STUDY IN THE UNITED-STATES [J].
JONES, RN ;
SADER, HS ;
ERWIN, ME ;
ANDERSON, SC ;
ALDRIDGE, KA ;
ALLEN, S ;
ANHALT, J ;
APPELBAUM, P ;
ARRINGTON, KL ;
AYERS, L ;
BAKER, C ;
BEAVIS, K ;
BERGER, J ;
BERTHOLD, G ;
BIRNBAUM, M ;
BOYLE, J ;
BRECHER, S ;
BRECKENRIDGE, R ;
BROWN, W ;
BRUCKNER, D ;
CARROLL, K ;
CHAUDHARY, S ;
CLEARY, T ;
COCKERILL, F ;
COYLE, M ;
CRAWFORD, V ;
DALTON, H ;
DOERN, G ;
EDBERG, S ;
GELFAND, M ;
GERLACH, EH ;
GOODMAN, N ;
GORZYNSKI, E ;
GREEN, P ;
GROSCHEL, D ;
HANFF, P ;
HANNA, B ;
HARRELL, L ;
HAUGEN, T ;
HEAGREY, M ;
HUMPHRIES, J ;
ISENBERG, H ;
JENKINS, S ;
JONES, E ;
JORGENSEN, J ;
KAUFFMAN, C ;
KEISER, J ;
KOCKA, F ;
KOMINOS, S ;
LEVISON, M .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 21 (02) :85-93
[6]  
JONES RN, 1995, IN PRESS CLIN MICROB
[7]   EVALUATION AND CHARACTERIZATION OF MULTIRESISTANT ENTEROCOCCUS-FAECIUM FROM 12 US-MEDICAL-CENTERS [J].
SADER, HS ;
PFALLER, MA ;
TENOVER, FC ;
HOLLIS, RJ ;
JONES, RN .
JOURNAL OF CLINICAL MICROBIOLOGY, 1994, 32 (11) :2840-2842
[8]   MICROBIOLOGICAL CHARACTERIZATION OF EVERNINOMICIN-B AND EVERNINOMICIN-D [J].
SANDERS, WE ;
SANDERS, CC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1974, 6 (03) :232-238
[9]  
WEINSTEIN MARVIN J., 1965, P24
[10]  
1993, M7A3 NCCLS